Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer
Version of Record online: 28 JUN 2008
© 2008 THE AUTHORS. JOURNAL COMPILATION © 2008 BJU INTERNATIONAL
Volume 102, Issue 2, pages 253–258, July 2008
How to Cite
Schwarzenbach, H., Chun, F. K.-H., Müller, I., Seidel, C., Urban, K., Erbersdobler, A., Huland, H., Pantel, K. and Friedrich, M. G. (2008), Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. BJU International, 102: 253–258. doi: 10.1111/j.1464-410X.2008.07600.x
- Issue online: 28 JUN 2008
- Version of Record online: 28 JUN 2008
- Accepted for publication 22 November 2007
- free plasma DNA;
- genetic aberrations;
- prostate cancer;
- serum diagnostics
To investigate whether a high frequency of allelic imbalance (AI) is associated with clinicopathological variables of patients with prostate cancer.
PATIENTS AND METHODS
We analysed loss of heterozygosity (LOH) and microsatellite (MS) instability (MSI) on circulating plasma DNA in a polymerase chain reaction (PCR)-based MS study of 230 patients with prostate cancer and 43 with benign prostatic hyperplasia (BPH) using a panel of 13 polymorphic MS markers.
The overall incidence of AI was significantly higher in primary tumours (34%) than in blood plasma samples from patients with prostate cancer (11%). Although LOH (2.0%) and MSI (1.5%) were also found in BPH plasma samples, their frequencies were low. AI identified in plasma samples from patients with prostate cancer could be retrieved in 63% of the paired tumour samples. The highest concordance of AI and retention of heterozygosity between tumour and plasma samples was 83% at the marker D8S360. There were high frequencies of LOH at the markers THRB, D7S522 and D8S137 in both types of specimens. The markers D11S898 and D11S1313 on the chromosome arm 11q showed frequent MSI. The comparison with established risk factors showed significant associations of an increase in prostate volume with AI at the combined markers D6S474/D7S522 in tumour tissues and at D7S522 in plasma samples (P < 0.04). In the primary tumours there was a further correlation of LOH at D11S1313 with increasing tPSA value (P = 0.005). The combination of total prostate-specific antigen (PSA) and % free PSA was associated with LOH at THRB in plasma samples.
Plasma-based MS analysis may have clinical value for the molecular staging of prostate cancer.